Literature DB >> 12787399

Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis.

Aihua Zhou1, Hikaru Ueno, Mayumi Shimomura, Ryojiro Tanaka, Toshiro Shirakawa, Hajime Nakamura, Masafumi Matsuo, Kazumoto Iijima.   

Abstract

BACKGROUND: We tested whether the entire soluble extracellular domain of the human transforming growth factor-beta (TGF-beta) type II receptor, fused to the Fc portion of human immunoglobulin G (IgG1) (Tbeta-ExR) and expressed in skeletal muscles by adenovirus-mediated gene transfer (AdTbeta-ExR), can ameliorate renal dysfunction and histologic progression in a rat experimental anti-glomerular basement membrane (GBM) nephritis.
METHODS: Anti-GBM nephritis was induced in Wistar Kyoto rats by an intravenous injection of anti-rat glomerular basement membrane (GBM) sera. At day 1 (24 hours after induction), AdTbeta-ExR (1 x 109 pfu/mL) was injected into the femoral muscle in the treatment group, and an adenovirus vector-expressing bacterial beta-galactosidase (AdLacZ) was injected into the control group. Then, clinical and histologic changes were examined for 3 weeks after the induction of anti-GBM nephritis.
RESULTS: Tbeta-ExR was detected in the serum at day 7, but the serum concentration of Tbeta-ExR had decreased below the detectable level by day 14. Although blood pressure and the degree of proteinuria were similar in both groups, the deterioration of renal function was significantly blunted in the treatment group. Crescent formation and interstitial fibrosis were also ameliorated in the treatment group. These histologic improvements were accompanied by the decreased interstitial infiltration of macrophages and the decreased alpha-smooth muscle actin (alpha-SMA)-positive cells in the glomeruli and the interstitium.
CONCLUSION: This study demonstrated for the first time that the blockade of TGF-beta action by AdTbeta-ExR in the early stage of anti-GBM nephritis ameliorates the clinical and histologic progression. In addition, this study shed light on the development of a specific gene therapy for human crescentic glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12787399     DOI: 10.1046/j.1523-1755.2003.00045.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  14 in total

Review 1.  The enigmatic parietal epithelial cell is finally getting noticed: a review.

Authors:  Takamoto Ohse; Jeffrey W Pippin; Alice M Chang; Ronald D Krofft; Jeffrey H Miner; Michael R Vaughan; Stuart J Shankland
Journal:  Kidney Int       Date:  2009-10-21       Impact factor: 10.612

2.  Clusterin attenuates the development of renal fibrosis.

Authors:  Gwon-Soo Jung; Mi-Kyung Kim; Yun-A Jung; Hye-Soon Kim; In-Sun Park; Bon-Hong Min; Ki-Up Lee; Jung-Guk Kim; Keun-Gyu Park; In-Kyu Lee
Journal:  J Am Soc Nephrol       Date:  2011-11-03       Impact factor: 10.121

3.  Inhibition of protein kinase CK2 prevents the progression of glomerulonephritis.

Authors:  Masateru Yamada; Susumu Katsuma; Tetsuya Adachi; Akira Hirasawa; Satoshi Shiojima; Tadashi Kadowaki; Yasushi Okuno; Taka-aki Koshimizu; Shigeo Fujii; Yumiko Sekiya; Yohei Miyamoto; Mitsutaka Tamura; Wako Yumura; Hiroshi Nihei; Makio Kobayashi; Gozoh Tsujimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-16       Impact factor: 11.205

4.  Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy.

Authors:  Jinhua Li; Naomi Vittoria Campanale; Rong Jiao Liang; James Antony Deane; John Frederick Bertram; Sharon Denise Ricardo
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

5.  Serum-starved adipose-derived stromal cells ameliorate crescentic GN by promoting immunoregulatory macrophages.

Authors:  Kazuhiro Furuhashi; Naotake Tsuboi; Asuka Shimizu; Takayuki Katsuno; Hangsoo Kim; Yosuke Saka; Takenori Ozaki; Yoshikazu Sado; Enyu Imai; Seiichi Matsuo; Shoichi Maruyama
Journal:  J Am Soc Nephrol       Date:  2013-03-07       Impact factor: 10.121

6.  Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis.

Authors:  Bart Smeets; Maria Lucia Angelotti; Paola Rizzo; Henry Dijkman; Elena Lazzeri; Fieke Mooren; Lara Ballerini; Eliana Parente; Costanza Sagrinati; Benedetta Mazzinghi; Elisa Ronconi; Francesca Becherucci; Ariela Benigni; Eric Steenbergen; Laura Lasagni; Giuseppe Remuzzi; Jack Wetzels; Paola Romagnani
Journal:  J Am Soc Nephrol       Date:  2009-10-29       Impact factor: 10.121

7.  The orphan nuclear receptor SHP attenuates renal fibrosis.

Authors:  Gwon-Soo Jung; Mi-Kyung Kim; Mi Sun Choe; Kyeong-Min Lee; Hye-Soon Kim; Young Joo Park; Hueng-Sik Choi; Ki-Up Lee; Keun-Gyu Park; In-Kyu Lee
Journal:  J Am Soc Nephrol       Date:  2009-07-30       Impact factor: 10.121

8.  Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling.

Authors:  Chang Joo Oh; Joon-Young Kim; Young-Keun Choi; Han-Jong Kim; Ji-Yun Jeong; Kwi-Hyun Bae; Keun-Gyu Park; In-Kyu Lee
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

9.  Urinary Transforming Growth Factor-beta 1 as a marker of response to immunosuppressive treatment, in patients with crescentic nephritis.

Authors:  Dimitrios S Goumenos; Pantelitsa Kalliakmani; Sotiris Tsakas; Florentia Sotsiou; John G Vlachojannis
Journal:  BMC Nephrol       Date:  2005-12-20       Impact factor: 2.388

10.  Crucial Role of Mesangial Cell-derived Connective Tissue Growth Factor in a Mouse Model of Anti-Glomerular Basement Membrane Glomerulonephritis.

Authors:  Naohiro Toda; Kiyoshi Mori; Masato Kasahara; Akira Ishii; Kenichi Koga; Shoko Ohno; Keita P Mori; Yukiko Kato; Keisuke Osaki; Takashige Kuwabara; Katsutoshi Kojima; Daisuke Taura; Masakatsu Sone; Taiji Matsusaka; Kazuwa Nakao; Masashi Mukoyama; Motoko Yanagita; Hideki Yokoi
Journal:  Sci Rep       Date:  2017-02-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.